In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.
In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.
复制标题
DOI:
10.4049/jimmunol.1300091
复制
发表时间:
2013-05-01
期刊:
影响因子:
--
通讯作者:
Via CS
中科院分区:
文献类型:
--
作者:
Soloviova K;Puliaiev M;Haas M;Via CS
A third signal is required for maturation of effector CD8 CTL in addition to TCR and CD28 engagement. Inflammatory cytokines can provide a third signal however in non-pathogen settings (i.e. anti-tumor responses), the identity of the third signal is not clear. A useful model for in vivo CD8 CTL in the absence of exogenous pathogens is the alloantigen driven parent-into F1 model of acute graft-vs.-host disease (GVHD) characterized by a strong TNF-dependent donor anti-host CD8 CTL T cell response. To determine whether TNF acts directly on donor T cells in a signal 3 manner, F1 mice received TNF receptor p55 knock out (KO) and/or p55 KO donor T cells. Donor p75 K but not p55 KO donor T cells failed to induce acute GVHD phenotype and instead induced a lupus-like chronic GVHD both short and long term due to quantitative and qualitative donor T cell defects i.e. reduced perforin, IFN-g and TNF production. Transfer of mixed or matched purified CD4 and CD8 T cells from WT or p75KO donors demonstrated that optimal CTL maturation required p75 signaling in both CD4 and CD8 T cells. Despite defective p75 KO CD4 help for CD8 CTL, p75KO CD4 help for B cells and autoimmunity was intact. These results provide a mechanism by which impaired CD8 CTL could contribute to reduced anti-viral and anti-tumor responses and autoimmunity reported in patients receiving TNF blockers. Our results support the idea that selective p55 blockade may be beneficial by reducing inflammation without compromising CD8 CTL.
登录
查看更多内容
DOI:
10.1084/jem.20020223
发表时间:
2002-09-16
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Fan GC;Singh RR
通讯作者:
Singh RR
影响因子:
7
作者:
Curtsinger JM;Mescher MF
通讯作者:
Mescher MF
DOI:
10.1016/j.clim.2010.01.005
发表时间:
2010-07
期刊:
Clinical immunology (Orlando, Fla.)
影响因子:
--
作者:
Foster AD;Haas M;Puliaeva I;Soloviova K;Puliaev R;Via CS
通讯作者:
Via CS
影响因子:
12.8
作者:
Eisenberg RA;Via CS
通讯作者:
Via CS
影响因子:
56.9
作者:
Badovinac, VP;Tvinnereim, AR;Harty, JT
通讯作者:
Harty, JT